Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Dec 17;12(12):CD013282.
doi: 10.1002/14651858.CD013282.pub2.

Addenbrooke's Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment

Lucy C Beishon  1 , Angus P Batterham  2 , Terry J Quinn  3 , Christopher P Nelson  1 , Ronney B Panerai  1 , Thompson Robinson  1 , Victoria J Haunton  1
Affiliations
Meta-Analysis

Addenbrooke's Cognitive Examination III (ACE-III) and mini-ACE for the detection of dementia and mild cognitive impairment

Lucy C Beishon et al. Cochrane Database Syst Rev. .

Abstract

Background: The number of new cases of dementia is projected to rise significantly over the next decade. Thus, there is a pressing need for accurate tools to detect cognitive impairment in routine clinical practice. The Addenbrooke's Cognitive Examination III (ACE-III), and the mini-ACE are brief, bedside cognitive screens that have previously reported good sensitivity and specificity. The quality and quantity of this evidence has not, however, been robustly investigated.

Objectives: To assess the diagnostic test accuracy of the ACE-III and mini-ACE for the detection of dementia, dementia sub-types, and mild cognitive impairment (MCI) at published thresholds in primary, secondary, and community care settings in patients presenting with, or at high risk of, cognitive decline.

Search methods: We performed the search for this review on 13 February 2019. We searched MEDLINE (OvidSP), Embase (OvidSP), BIOSIS Previews (ISI Web of Knowledge), Web of Science Core Collection (ISI Web of Knowledge), PsycINFO (OvidSP), and LILACS (BIREME). We applied no language or date restrictions to the electronic searches; and to maximise sensitivity we did not use methodological filters. The search yielded 5655 records, of which 2937 remained after we removed duplicates. We identified a further four articles through PubMed 'related articles'. We found no additional records through reference list citation searching, or grey literature.

Selection criteria: Cross-sectional studies investigating the accuracy of the ACE-III or mini-ACE in patients presenting with, or at high risk of, cognitive decline were suitable for inclusion. We excluded case-control, delayed verification and longitudinal studies, and studies which investigated a secondary cause of dementia. We did not restrict studies by language; and we included those with pre-specified thresholds (88 and 82 for the ACE-III, and 21 or 25 for the mini-ACE).

Data collection and analysis: We extracted information on study and participant characteristics and used information on dementia and MCI prevalence, sensitivity, specificity, and sample size to generate 2×2 tables in Review Manager 5. We assessed methodological quality of included studies using the QUADAS-2 tool; and we assessed the quality of study reporting with the STARDdem tool. Due to significant heterogeneity in the included studies and an insufficient number of studies, we did not perform meta-analyses.

Main results: This review identified seven studies (1711 participants in total) of cross-sectional design, four examining the accuracy of the ACE-III, and three of the mini-ACE. Overall, the majority of studies were at low or unclear risk of bias and applicability on quality assessment. Studies were at high risk of bias for the index test (n = 4) and reference standard (n = 2). Study reporting was variable across the included studies. No studies investigated dementia sub-types. The ACE-III had variable sensitivity across thresholds and patient populations (range for dementia at 82 and 88: 82% to 97%, n = 2; range for MCI at 88: 75% to 77%, n = 2), but with more variability in specificity (range for dementia: 4% to 77%, n = 2; range for MCI: 89% to 92%, n = 2). Similarly, sensitivity of the mini-ACE was variable (range for dementia at 21 and 25: 70% to 99%, n = 3; range for MCI at 21 and 25: 64% to 95%, n = 3) but with more variability specificity (range for dementia: 32% to 100%, n = 3; range for MCI: 46% to 79%, n = 3). We identified no studies in primary care populations: four studies were conducted in outpatient clinics, one study in an in-patient setting, and in two studies the settings were unclear.

Authors' conclusions: There is insufficient information in terms of both quality and quantity to recommend the use of either the ACE-III or mini-ACE for the screening of dementia or MCI in patients presenting with, or at high risk of, cognitive decline. No studies were conducted in a primary care setting so the accuracy of the ACE-III and mini-ACE in this setting are not known. Lower thresholds (82 for the ACE-III, and 21 for the mini-ACE) provide better specificity with acceptable sensitivity and may provide better clinical utility. The ACE-III and mini-ACE should only be used to support the diagnosis as an adjunct to a full clinical assessment. Further research is needed to determine the utility of the ACE-III and mini-ACE for the detection of dementia, dementia sub-types, and MCI. Specifically, the optimal thresholds for detection need to be determined in a variety of settings (primary care, secondary care (inpatient and outpatient), and community services), prevalences, and languages.

PubMed Disclaimer

Conflict of interest statement

Lucy C Beishon: none known. Angus P Batterham: none known. Terry J Quinn: none known. Ronney B Panerai: none known. Christopher P Nelson: none known. Thompson Robinson: none known. Victoria J Haunton: none known.

Figures

1
1
Study flow diagram
2
2
Risk of bias and applicability concerns graph: review authors' judgements about each domain presented as percentages across included studies
3
3
Risk of bias and applicability concerns summary: review authors' judgements about each domain for each included study
4
4
Forest plot of ACE‐III for the detection of dementia at a threshold of 88.
5
5
Forest plot of 6 ACE‐III for the detection of dementia at a threshold of 82.
6
6
Forest plot of 8 ACE‐III for the detection of post‐stroke cognitive impairment at a threshold of 82.
7
7
Forest plot of ACE‐III for the detection of MCI at a threshold of 88.
8
8
Forest plot of Mini‐ACE for the detection of dementia at a threshold of 25.
9
9
Forest plot of Mini‐ACE for the detection of MCI at a threshold of 25.
10
10
Forest plot of Mini‐ACE for the detection of dementia at a threshold of 21.
11
11
Forest plot of Mini‐ACE for the detection of MCI at a threshold of 21.
1
1. Test
Mini‐ACE for the detection of dementia at a threshold of 25.
2
2. Test
Mini‐ACE for the detection of dementia at a threshold of 21.
3
3. Test
Mini‐ACE for the detection of MCI at a threshold of 25.
4
4. Test
Mini‐ACE for the detection of MCI at a threshold of 21.
5
5. Test
ACE‐III for the detection of dementia at a threshold of 88.
6
6. Test
ACE‐III for the detection of dementia at a threshold of 82.
7
7. Test
ACE‐III for the detection of MCI at a threshold of 88.
8
8. Test
ACE‐III for the detection of post‐stroke cognitive impairment.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD013282

References

References to studies included in this review

Hobson 2016 {published data only}
    1. Hobson P, Rohoma KH, Wong SP, Kumwenda MJ. The utility of the Mini‐Addenbrooke's Cognitive Examination as a screen for cognitive impairment in elderly patients with chronic kidney disease and diabetes. Dementia and Geriatric Cognitive Disorders Extra 2016;6(3):541‐8. - PMC - PubMed
Jubb 2015 {published data only}
    1. Jubb MT, Evans JJ. An investigation of the utility of the Addenbrooke’s Cognitive Examination III in the early detection of dementia in memory clinic patients aged over 75 years. Dementia and Geriatric Cognitive Disorders 2015;40(3‐4):222‐32. - PubMed
Larner 2019 {published data only}
    1. Larner AJ. MACE for diagnosis of dementia and MCI: examining cut‐offs and predictive values. Diagnostics (Basel) 2019;9(2):pii: E51. - PMC - PubMed
Lees 2017 {published data only}
    1. Lees RA, Hendry K, Broomfield N, Stott D, Larner AJ, Quinn TJ. Cognitive assessment in stroke: feasibility and test properties using differing approaches to scoring of incomplete items. International Journal of Geriatric Psychiatry 2016;32(10):1072‐8. - PubMed
Li 2019 {published data only}
    1. Xiaojia L, Lili Y, Jia Y, Nengwei Y, Fang Y. Validation study of the Chinese version of Addenbrooke’s Cognitive Examination III for diagnosing mild cognitive impairment and mild dementia. Journal of Clinical Neurology (Seoul, Korea) 2019;15(3):313‐20. - PMC - PubMed
Takenoshita 2019 {published data only}
    1. Shintaro T, Seishi T, Hidenori Y, Megumi Y, Mayumi Y, Nao I, et al. Validation of Addenbrooke’s Cognitive Examination III for detecting mild cognitive impairment and dementia in Japan. BMC Geriatrics 2019;19(1):1120‐4. - PMC - PubMed
Yang 2019 {published data only}
    1. Yang L, Li X, Yin J, Yu N, Liu J, Ye F. A validation study of the Chinese Version of the Mini‐Addenbrooke’s Cognitive Examination for screening mild cognitive impairment and mild dementia. Journal of Geriatric Psychiatry and Neurology 2019;32(4):205‐10. - PubMed

Additional references

Alzheimer's Disease International 2013
    1. Alzheimer's Disease International. Ideas and advice on developing and implementing a national dementia plan. Alzheimer's Disease International 2013:13‐4.
Alzheimer's Research UK 2017
    1. Alzheimer's Research UK. Population screening and targeted case finding policy statement. www.alzheimersresearchuk.org/wp‐content/uploads/2015/01/ARUK‐Screening‐a... (accessed 31 August 2018).
Alzheimer's Society 2015
    1. Alzheimer's Society. Helping you to assess cognition. a practical toolkit for clinicians. Alzheimer's Society 2015:1‐40.
Alzheimer's Society 2016
    1. Alzheimer's Society. Demography. https://www.alzheimers.org.uk/info/20091/position_statements/93/demography (accessed 31 August 2018).
American Psychiatric Association 2000
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
American Psychiatric Association 2013
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐V). 5th Edition. Washington, DC: American Psychiatric Association, 2013.
Aminzadeh 2007
    1. Aminzadeh F, Byszewski A, Molnar F J, Eisner M. Emotional impact of dementia diagnosis: exploring persons with dementia and caregivers' perspectives. Aging & Mental Health 2007;11(3):281‐90. - PubMed
Aminzadeh 2012
    1. Aminzadeh F, Molnar FJ, Dalziel WB, Ayotte D. A review of barriers and enablers to diagnosis and management of persons with dementia in primary care. Canadian Geriatrics Journal 2015;15(3):85‐94. - PMC - PubMed
Arevalo‐Rodriguez 2015
    1. Arevalo‐Rodriguez I, Smailagic N, Roque I Figuls M, Ciapponi A, Sanchez‐Perez E, Giannakou A, et al. Mini‐Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD010783.pub2] - DOI - PMC - PubMed
Attems 2014
    1. Attems J, Jellinger K A. The overlap between vascular disease and Alzheimer's disease — lessons from pathology. BMC Medicine 2014;12:206. - PMC - PubMed
Banerjee 2016
    1. Banerjee S, Farina N, Hughes L, Woong K, Sim K. UK‐Korea Initiative: Optimizing the Impacts of National Dementia Strategies. https://www.bsms.ac.uk/_pdf/cds/korea‐presentations/optimizing‐the‐impac....
Birks 2013
    1. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD004744.pub3] - DOI - PMC - PubMed
Brainin 2014
    1. Brainin M, Tuomilehto J, Heiss WD, Bornsteim NM, Bath PM, Teuschl Y, et al. Post‐stroke cognitive decline: an update and perspectives for clinical research. European Journal of Neurology 2014;22(2):229‐e16. - PubMed
Care Quality Commission 2014
    1. Care Quality Commission. Cracks in the Pathway. www.cqc.org.uk/sites/default/files/20141009_cracks_in_the_pathway_final_... (accessed 31 August 2018):4‐48.
Chen 2013
    1. Chen S, Boyle LL, Conwell Y, Chiu H, Li L, Xiao S. Dementia care in rural China. Mental Health in Family Medicine 2013;10(3):133‐41. - PMC - PubMed
Chodosh 2004
    1. Chodosh J, Petitti DB, Elliott M, Hays RD, Crooks VC, Reuben D B, et al. Physician recognition of cognitive impairment: evaluating the need for improvement. Journal of the American Geriatrics Society 2004;52(7):1051‐9. - PubMed
Crawford 2012
    1. Crawford S, Whitnall L, Robertson J, Evans JJ. A systematic review of the accuracy and clinical utility of the Addenbrooke's Cognitive Examination and the Addenbrooke's Cognitive Examination ‐ Revised in the diagnosis of dementia. International Journal of Geriatric Psychiatry 2012;27(7):659‐69. - PubMed
Creavin 2016
    1. Creavin ST, Wisniewski S, Noel‐Storr AH, Trevelyan CM, Hampton T, Rayment D, et al. Mini‐Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 2016, Issue 1. [DOI: 10.1002/14651858.CD011145.pub2] - DOI - PMC - PubMed
Davis 2013
    1. Davis DH, Creavin ST, Noel‐Storr A, Quinn TJ, Smailagic N, Hyde C, et al. Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross‐sectional and delayed‐verification studies. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010775.pub2] - DOI - PMC - PubMed
Davis 2015
    1. Davis DH, Creavin ST, Yip JL, Noel‐Storr AH, Brayne C, Cullum S. Montreal Cognitive Assessment for the diagnosis of Alzheimer’s disease and other dementias. Cochrane Database of Systematic Reviews 2015, Issue 10. [DOI: 10.1002/14651858.CD010775.pub2] - DOI - PMC - PubMed
de Vugt 2013
    1. Vugt ME, Verhey FR. The impact of early dementia diagnosis and intervention on informal caregivers. Progress in Neurobiology 2013;110:54‐62. - PubMed
Dichgans 2017
    1. Dichgans M, Leys D. Vascular cognitive impairment. Circulation Research 2017;120(3):573‐91. - PubMed
Ganguli 2004
    1. Ganguli M, Rodriguez E, Mulsant B, Richards S, Pandav R, Bilt J V, et al. Detection and management of cognitive impairment in primary care: The Steel Valley Seniors Survey. Journal of the American Geriatrics Society 2004;52(10):1668‐75. - PubMed
Harper 2014
    1. Harper L, Barkhof F, Scheltens P, Schott JM, Fox NC. An algorithmic approach to structural imaging in dementia. Journal of Neurology, Neurosurgery, and Psychiatry 2014;85(6):692‐8. - PMC - PubMed
Harrison 2016
    1. Harrison JK, Stott DJ, McShane R, Noel‐Storr AH, Swann‐Price RS, Quinn TJ. Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the early diagnosis of dementia across a variety of healthcare settings. Cochrane Database of Systematic Reviews 2016, Issue 11. [DOI: 10.1002/14651858.CD011333.pub2] - DOI - PMC - PubMed
Health Quality Ontario 2014
    1. Health Quality Ontario. The appropriate use of neuroimaging in the diagnostic work‐up of dementia. Ontario Health Technology Assessment Series 2014;14(1):1‐64. - PMC - PubMed
Hsieh 2013
    1. Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke's Cognitive Examination III in frontotemporal dementia and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2013;36:242‐50. - PubMed
Hsieh 2015
    1. Hsieh S, McGrory S, Leslie F, Dawson K, Ahmed S, Butler CR, et al. The Mini‐Addenbrooke's Cognitive Examination: a new assessment tool for dementia. Dementia and Geriatric Cognitive Disorders 2015;39(1‐2):1‐11. - PMC - PubMed
Kalaria 2010
    1. Kalaria RN, Maestre GE, Arizaga R, Friedland RP, Galasko D, Hall K, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurology 2008;7(9):812‐26. - PMC - PubMed
Korolev 2016
    1. Korolev IO, Symonds LL, Bozoki AC, Herholz K. Predicting progression from mild cognitive impairment to Alzheimer's dementia using clinical, MRI, and plasma biomarkers via probabilistic pattern classification. PLoS One 2016;11(2):e0138866. - PMC - PubMed
Larner 2014
    1. Larner AJ, Mitchell AJ. A meta‐analysis of the accuracy of the Addenbrooke's Cognitive Examination (ACE) and the Addenbrooke's Cognitive Examination‐Revised (ACE‐R) in the detection of dementia. International Psychogeriatrics / IPA 2014;26(4):555‐63. - PubMed
Lin 2013
    1. Lin JS, O'Connor E, Rossom RC, Perdue LA, Eckstrom E. Screening for cognitive impairment in older adults: a systematic review for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2013;159(9):601‐12. - PubMed
Lund 1994
    1. The Lund and Manchester Groups. Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57(4):416‐8. - PMC - PubMed
Malouf 2004
    1. Malouf R, Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: 10.1002/14651858.CD004395.pub2] - DOI - PubMed
Mandal 2006
    1. Mandal PK, Pettegrew JW, Masliah E, Hamilton R L, Mandal R. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease. Neurochemical Research 2006;31(9):1153‐62. - PubMed
McKeith 2006
    1. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease 2006;9(3 Suppl):417‐23. - PubMed
McKhann 1984
    1. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34(7):939‐44. - PubMed
McKhann 2011
    1. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Clifford JR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging‐Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer's & Dementia 2011;7(3):263‐9. - PMC - PubMed
Mioshi 2006
    1. Mioshi E, Dawson K, Mitchell J, Arnold R, Hodges JR. The Addenbrooke's Cognitive Examination Revised (ACE‐R): a brief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry 2006;21(11):1078‐85. - PubMed
Mirza 2017
    1. Mirza N, Panagioti M, Waheed MW, Waheed W. Reporting of the translation and cultural adaptation procedures of the Addenbrooke's Cognitive Examination version III (ACE‐III) and its predecessors: a systematic review. BMC Medical Research Methodology 2017;17(1):141. - PMC - PubMed
Nasreddine 2005
    1. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 2005;53(4):695‐9. - PubMed
Ngo 2015
    1. Ngo J, Holroyd‐Leduc JM. Systematic review of recent dementia practice guidelines. Age and Ageing 2015;44:25‐53. - PubMed
NICE 2011
    1. NICE. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. www.nice.org.uk/guidance/ta217/chapter/1‐guidance (accessed 31 August 2018).
NICE 2018
    1. NICE. Dementia: assessment, management and support for people living with dementia and their carers. www.nice.org.uk/guidance/ng97 (accessed 31 August 2018). - PubMed
Noel‐Storr 2014
    1. Noel‐Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ. Reporting standards for studies of diagnostic test accuracy in dementia. The STARDdem Initiative. Neurology 2014;83(4):364‐73. - PMC - PubMed
Noone 2015
    1. Noone P. Addenbrooke's Cognitive Examination‐III. Occupational Medicine 2015;65(5):418‐20. - PubMed
Panegyres 2016
    1. Panegyres PK, Berry R, Burchell J. Early dementia screening. Diagnostics (Basel) 2016;6(1):pii: E6. - PMC - PubMed
Petersen 2004
    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine 2004;256(3):183‐94. - PubMed
Petersen 2013
    1. Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, et al. Mild cognitive impairment due to Alzheimer disease in the community. Annals of Neurology 2013;74(2):199‐208. - PMC - PubMed
Prince 2015
    1. Prince M, Wimo A, Guerchet M, Ali GC, Wu Y, Prina M. World Alzheimer Report 2015. The global impact of dementia. Alzheimer's Disease International. www.alz.co.uk/research/WorldAlzheimerReport2015.pdf (accessed 31 August 2018).
Prince 2016
    1. Prince M, Comas‐Herrera A, Knapp M, Guerchet M, Karagiannidou M. World Alzheimer Report 2016: Improving healthcare for people living with dementia: coverage, quality and costs now and in the future. Available at www.alz.co.uk/research/WorldAlzheimerReport2016.pdf.
Rascovsky 2011
    1. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011;134(Pt 9):2456‐77. - PMC - PubMed
Review Manager 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Robinson 2015
    1. Robinson L, Tang E, Taylor J P. Dementia: timely diagnosis and early intervention. BMJ 2015;350:h3029. - PMC - PubMed
Román 1993
    1. Román GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS‐AIREN International Workshop. Neurology 1993;43(2):250‐60. - PubMed
Samsi 2014
    1. Samsi K, Manthorpe J. Care pathways for dementia: current perspectives. Clinical Interventions in Aging 2014;9:2055‐63. - PMC - PubMed
Takahashi 2017
    1. Takahashi RH, Nagao T, Gouras GK. Plaque formation and the intraneuronal accumulation of beta‐amyloid in Alzheimer's disease. Pathology International 2017;67(4):185‐93. - PubMed
Tsoi 2015
    1. Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive tests to detect dementia: a systematic review and meta‐analysis. JAMA Internal Medicine 2015;175(9):1450‐8. - PubMed
Valcour 2000
    1. Valcour VG, Masaki KH, Curb JD, Blanchette PL. The detection of dementia in the primary care setting. Archives of Internal Medicine 2000;160(19):2964‐8. - PubMed
Velayudhan 2014
    1. Velayudhan L, Ryu SH, Raczek M, Philpot M, Lindesay J, Critchfield M, et al. Review of brief cognitive tests for patients with suspected dementia. International Psychogeriatrics / IPA 2014;26(8):1247‐62. - PMC - PubMed
Walker 2017
    1. Walker IF, Lord PA, Farragher TM. Variations in dementia diagnosis in England and association with general practice characteristics. Primary Health Care Research & Development 2017;18(3):235‐41. - PubMed
Whiting 2011
    1. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS‐2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529‐36. - PubMed
Williamson 2018
    1. Williamson J, Larner A. MACE for the Diagnosis of Dementia and MCI: 3‐Year Pragmatic Diagnostic Test Accuracy Study. Dementia and Geriatric Cognitive Disorders 2018;45:300‐307. - PubMed
World Health Organization 2010
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD). Geneva (Switzerland): World Health Organization, 2010.
World Health Organization 2018
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems (ICD). Geneva (Switzerland): World Health Organization, 2018.
Zhao 2016
    1. Zhao M, Lv X, Tuerxun M, He J, Luo B, Chen W, et al. Delayed help seeking behaviour in dementia care: preliminary findings from the Clinical Pathway for Alzheimer’s Disease in China (CPAD) study. International Psychogeriatrics / IPA 2016;28(2):211‐9. - PubMed

Publication types

MeSH terms